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Abstract: Microvesicles (MVs) include a heterogeneous population of vesicles released as exosomes from the endosomal 
compartment or as shedding vesicles from the cell surface of different cell types. The broad spectrum of biological 
activities displayed by MVs candidate them to a pivotal role in cell-to-cell communication. It is now recognized that they 
constitute an integral part of the intercellular microenvironment acting as vehicle for information transfer. After receptor-
ligand interaction with target cells, MVs may directly stimulate the cells or may transfer from the cell of origin various 
bioactive molecules including membrane receptors, bioactive lipids and proteins. In addition, MVs may induce epigenetic 
changes in target cells by delivering specific subsets of mRNA and microRNA associated with different cell functions 
such as differentiation of blood cells, metabolic pathways and modulation of immune response. In vivo, MVs released 
from mesenchymal stem cells may account for the described paracrine action of these cells in tissue regeneration. A bi-
directional exchange of genetic information between stem and injured cells could be envisaged: i) transcripts delivered by 
MVs from injured cells may reprogram the phenotype of stem cells to acquire specific features of the tissue; ii) transcripts 
delivered by MVs from stem cells may limit tissue injury and induce cell cycle re-entry of resident cells leading to tissue 
self-repair. 
This review presents an overview of the many biological actions of MVs produced by stem cells that may be exploited in 
regenerative medicine to repair damaged tissues as an alternative to stem cell-based therapy. 
Keywords: Angiogenesis, apoptosis, cell communication, exosomes, inflammation, kidney repair, liver repair, mesenchymal 
stem cells, microvesicles, signal transduction, stem cells, transport of genetic information, tissue regeneration. 
INTRODUCTION 
 The understanding of the cellular and molecular 
mechanisms involved in tissue repair provides new insights 
for regenerative medicine. A number of acute and chronic 
diseases may benefit from therapeutic strategies aimed to 
favor repair and regeneration of injured tissues. Therefore, 
on this perspective it is important to learn how we can use 
the reparative resource of the organism to activate its own 
protective mechanisms. At present, most regenerative 
processes are thought to be performed by stem/progenitor 
cells. These cells are virtually present in all adult tissues and 
organs and they may participate in the physiological cell 
turnover, growth, homeostasis and repair of limited injuries 
of many tissues. 
 Stem/progenitor cell transplantation has been suggested 
as an approach for treating many types of diseases. It has 
been shown that mesenchymal stem cells (MSCs) can 
stimulate regeneration of several tissues /organs after injury 
[1, 2]. 
 In preclinical studies different types of stem cells isolated 
from adult tissues have been used for regeneration of  
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damaged organs such as heart, liver, kidney, etc. [3-9]. These 
include bone marrow derived mononuclear cells, 
hematopoietic stem cells, MSCs, skeletal muscle myoblasts 
and the so-called cardiac stem cells. To date stem cell 
therapy in clinical settings has been employed for the 
treatment of a variety of severe pathologic conditions, such 
as cardiovascular, neurodegenerative, metabolic and 
immuno-mediated diseases. [5, 10] Several clinical trials are 
ongoing in different countries in particular with MSCs [3-6] 
(for the clinical trials see: www.clinicaltrial.gov). Despite the 
observed beneficial effects, there is no consistent evidence 
that the cells employed generate organ-specific cell 
population, able to replace the cell loss after injury. Indeed, 
transdifferentiation has not consistently been proved in many 
experimental models, and the phenomenon of cell fusion is 
considered a rare event. Therefore, it has been suggested that 
stem cells may act as producers of bioactive molecules 
(growth factors, cytokines, etc.) that account for the 
observed beneficial effects [1, 11]. It has been shown that 
MSCs produce and secrete a broad variety of cytokines, 
chemokines, and growth factors that may potentially be 
involved in regeneration, including vascular endothelial 
growth factor (VEGF), hepatocyte growth factor (HGF), 
platelet-derived growth factor (PDGF), and other angiogenic 
factors, neurotrophic factors such as brain-derived 
neurotrophic factor (BDNF), nerve growth factor (NGF), 
glial cell-derived neurotrophic factor (GDNF) [1, 2, 12, 13]. 
Furthermore, hypoxic stress increases the production of 
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several of these factors. Indeed, tissue concentrations of 
these growth factors were found to be significantly increased 
in injured tissue after treatment with MSCs [14, 15]. A 
strong support for a paracrine mechanism in tissue repair 
comes from experiments in which the administration of 
conditioned medium from MSCs was shown to mimic the 
beneficial effects observed after stem cell therapy [16, 17]. 
Gnecchi and colleagues [18]demonstrated that conditioned 
medium from MSCs, particularly from genetically modified 
MSCs overexpressing Akt-1, exerts cardiomyocyte 
protection from ischemia. Takahashi et al. [19] injected 
conditioned medium from MSCs into acutely infarcted 
hearts and observed increased capillary density, decreased 
infarct size, and improved cardiac function compared with 
controls. These observations stimulated research aimed to 
identify the factors that mediate the biological effect of 
MSCs. On the other hand, a major limit for MSC clinical 
application is their inherent heterogeneity and variation 
associated with cell expansion. Additionaly, in vitro cell 
processing and expansion could induce changes that increase 
the risk of their therapeutic applications. Moreover, MSCs 
may undergo unwanted differentiation in vivo such as 
adipogenic differentiation in the kidney [7] or the osteogenic 
differentiation in the heart [20]. Therefore, identification of 
the molecules involved in the paracine action of stem cells 
may non only provide information on the mechanism of 
action, but also open new therapeutic options. We recently 
found that microvesicles (MVs) derived from adult stem 
cells may be an integral component of the paracrine 
mechanism involved in tissue regeneration [21]. MVs 
participate in cell-to-cell communications and regulate many 
cellular processes including proliferation, migration and 
differentiation by transfer of proteins, bioactive lipids, 
nucleic acids and other molecules from one cell to another 
[22, 23]. Therefore, MVs may transfer from stem cells to 
target cells critical information that may serve for tissue 
regeneration after injury. Since the use of stem cells in 
medicine could lead to tumorigenesis and other negative 
consequences [24], MVs may constitute an alternative 
therapeutic tool in regenerative medicine. At variance of 
stem cells, MVs cannot proliferate but can deliver to 
recipient cells growth factors, receptors, ligands, and even 
genetic information. The rationale for MV employment in 
regenerative medicine is based on the evidence that MVs 
may stimulate the endogenous repair by inducing a stem 
cell-like phenotype in differentiated tissue resident cells or 
by activating tissue resident stem cells. Moreover, it may be 
envisaged that custom-engineered MVs may be used for 
delivery of high levels of regenerative growth factors or 
nucleic acids. 
CHARACTERISTICS AND NATURE OF MVs 
 The term «microvesicles» includes all secreted or 
extracellular membrane vesicles such as microparticles, 
ectosomes, exosomes, apoptotic bodies and shedding 
vesicles, or vesicles designed by their functions such as 
argosomes, oncosomes, promininosomes, prostasomes, etc. 
[22, 25-27]. MVs contain membrane and soluble proteins, 
nucleic acids and other bioactive molecules. It is thought that 
MVs originate through two distinct mechanisms: 1) blebbing 
of the plasma membrane with production of shedding 
vesicles also defined as ectosomes or microparticles; 2) the 
endosomal processing and release of cytosol and plasma 
membrane material as part of exosomes. Many (if not all) 
cell types may produce MVs [28]. Another types of shedding 
vesicles are the apoptotic bodies released from dying cells. 
Apoptotic MVs often contain DNA as remnant of nucleus 
[22, 25, 29]. 
Shedding Microvesicles or Ectosomes 
 Shedding microvesicles are membranous vesicles with a 
size greater than 100 nm in diameter, extruded from the 
plasma membrane of many types of cells [30-32]. These 
MVs are enriched of lipid raft-associated molecules 
including tissue factor (TF) and flotillin-1 [33]. Formation of 
shedding MVs occurs through budding of plasma membrane, 
collecting specific transmembrane and cytosol proteins. This 
phenomenon is characterized by the exposure of 
phosphatidylserine (PS) residues on the outer surfaces of 
MVs [34]. The process happens under the control of several 
enzymes such as calpain, flippase, floppase, scramblase and 
gelsolin [35]. MVs carry specific marker molecules from the 
donor cells, for example platelet-derived MVs contain 
platelet/endothelial cell adhesion molecule (PECAM-1), 
while MVs from gliomas carry oncogenic growth factor 
receptors (e.g., EGFRvIII) [25]. Other MVs were shown to 
contain cytokines and chemokines (e.g., IL-1?, and IL-8), 
VEGF and fibroblast growth factor 2 (FGF2) derived from 
donor cells [31, 35-38]. 
 The mechanisms of MV release have been described in 
different types of cells. Firstly, the microparticles released 
from activated platelets were investigated. It was shown that 
blebbing of plasma membrane is associated with changes in 
membrane lipid asymmetry. Each of the two leaflets of the 
membrane bilayer has a specific composition. Acidic 
aminophospholipids (PS, phosphatidylethanolamine) are 
concentrated specifically in the inner side, whereas neutral 
phospholipids (phosphatidylcholine, sphingomyelin) are 
enriched in the external one. The transbilayer lipid 
distribution is under the control of several enzymes like 
flippase, floppase, and a lipid scramblase [39]. The increase 
of cytosolic Ca2+ following cell stimulation leads to 
activation of these enzymes resulting to surface exposure of 
PS. The subsequent cytoskeleton degradation by a Ca2+-
dependent proteolysis induces shedding of MVs from the 
cell surface [40, 41]. PS in the outer membrane acts as a 
template for the prothrombinase complex assembly and for 
coagulation activation [42, 43]. 
 Endothelial cells, monocytes, vascular smooth muscle 
cells, and hepatocytes can also release MVs after activation 
by bacterial lipopolysaccharides, inflammatory cytokines 
(tumor necrosis factor- ? (TNF?), interleukin 1 (IL-1)), 
aggregated lowdensity lipoproteins, or reactive oxygen 
species [44-47]. All these stimuli increase the level of 
intracellular Ca2+ that is crucial for MV release [48]. 
 Other molecular mechanisms were described in neural 
cells (CNS phagocytes, microglia). The key players in these 
cells are acidic sphingomyelinase (aSMase) and P2X7 
receptor. The sequence of events is: 1) ATP (dying cells 
release ATP) activates P2X7 receptor; 2) receptor 
stimulation leads to the activation of aSMase with rapid 
sphingomyelin hydrolysis; 3) sphingomyelin hydrolysis 
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results in increased membrane fluidity [49, 50], leading to 
membrane blebbing and MV shedding [36, 51, 52]. Dying 
cells by releasing ATP, may stimulate other cells to release 
MVs containing proinflammatory cytokines (IL-1?) and may 
regulate the clearance of cellular debris. 
Exosomes 
 Exosomes are MVs of 40–100 nm size with an 
endosomal origin. Exosomes originate upon fusion of 
multivesicular bodies with the plasma membrane. Exocytosis 
of multivesicular bodies has been described for various cell 
types, including reticulocytes [53-55], B-lymphocytes, 
dendritic cells [58], mast cells [59], platelets [32], and 
others. Exosomes share the biochemical characteristics with 
the vesicles of the multivesicular bodies. The biogenesis of 
exosomes is regulated by distinct cellular pathways [22, 60, 
61]. The release of exosomes occurs by exocytosis and may 
be either constitutive triggered by a Ca2+-independent 
mechanism or consequent to stimulation by a Ca2+-regulated 
mechanism. The constitutive exocytosis occurs in almost all 
cell types and it is involved in the secretion of newly 
synthesized proteins. Exocytosis dependent on cell activation 
is initiated by an endosomal formation following the 
invagination of endocytic vesicles, that fuse with the early 
endosomes [62]. The initial steps of exosomes secretion is 
controlled by the endosomal sorting complex required for 
transport (ESCRT) [63]. Inward invaginations of plasma 
membrane lead to formation intracellular vacuoles (early 
endosomes) that, under control of ESCRT, mature into the 
late endosome/multivesicular bodies that can give rise to 
released exosomes following the redirection and fusion of 
multivesicular bodies with the plasma membrane. There is 
no clear evidence that ESCRT takes part in the molecular 
sorting of exosomal contents. However, some components of 
ESCRT complex such as Alix are found in exosomes [64, 
65]. Alix is a protein that associates with the ESCRT 
machinery known to be required for sorting of the transferrin 
receptor [66]. An other molecular mechanism of exosome 
release includes ceramide [67, 68] that promotes membrane 
invaginations [69]. 
 Exosomes contain not only cytosol constituents but also 
the extracellular domains of transferring receptors [62]. 
Therefore, exosomes are the result of the secretion process of 
the endosomal components of the cells. 
 When compared with shedding microvesicles, exosomes 
contain different set of molecules [25, 27, 70, 71]. Exosomes 
contain some marker proteins such as Alix, TSG101, 
HSC70, CD63, CD81, CD9. Moreover, the lipid content of 
exosomes include low phosphatidylserine exposure, 
ceramide, lipid rafts and sphingomyelin, whereas shedding 
microvesicles expose high level of phosphatidylserine [28]. 
The nucleic acid content is presented in both structures. The 
biological fluid as well as MVs released in vitro by cells 
contain a mixture of exosomes and shedding vesicles and the 
collection process by differential ultracentrifugation does not 
allow a complete separation. For this reason frequently the 
term MVs is used to indicate both exosomes and shedding 
microvesicles. At present, functional differences between 
exosomes and microvesicles have not been extensively 
investigated. 
CHEMICAL COMPOSITION OF MVs 
 The function of MVs depends on their chemical 
composition. Usually MVs carry some specific lipids, 
membrane proteins, which help them to interact with defined 
cell, some soluble proteins (growth factors, RNA-binding 
proteins) RNA, sometimes DNA and other bioactive 
molecules. There are molecules that are common for every 
type of MVs and some that are specific for the cells of 
origin, the type of MVs, the culture conditions etc. 
 The protein content of MVs has been analyzed from 
various cell types and body fluids by several methods such 
as Western blot, Mass Spectrometry, fluorescence-activated 
cell sorting and immunoelectron microscopy. Proteomic 
analysis was performed on MVs from many different types 
of cells or body fluids [72-90]. Some proteins (HSPA8, 
CD63, ACTB, GAPDH, ENO1, HSP90AA1, CD9, CD81, 
YWHAZ, PKM2) were found in most of MVs [91], 
suggesting that they are necessary for MV function. 
However, the majority of MV proteins varies depending on 
the cell type and on the tissue of origin [79]. In addition, 
some proteins are specifically accumulated in MVs [28]. 
 MVs do not transport only proteins and lipids. They carry 
also different RNA species [77]. Indeed, it has been shown 
that MVs contain mRNA and microRNA (miRNA), but a 
very little amount of ribosomal RNA. Microarray analysis 
revealed that some RNAs are specifically concentrated in 
MVs. In the same manner as proteins, RNAs from MVs 
include some common for most MVs and others specific for 
the cell- and tissue-of origin. Experiments of in vitro 
translation proved that the mRNAs shuttled by MVs are 
functional [77]. These different RNA species are likely to be 
specifically packed into the MVs by active sorting 
mechanisms that at present are largely unknown. Several 
RNA-binding proteins are detectable in MVs including 
HNRNPA2B1, HNRPAB, ILF2, NCL, NPM1, RPL10A, 
RPL5, RPLP1, RPS12, RPS19, SNRPG, TROVE2 [92], 
ESCRT-II [93]. Some of these RNA-binding proteins play a 
role in RNA stabilization, others are involved in its fate as in 
the case of Staufen protein family that plays a critical role in 
miRNA maturation [94]. MVs are considered to be a unique 
mechanism for transport of nucleic acids at long distance 
within the body as they provide a protection from nucleases. 
The process of RNA secretion has been shown to be largely 
energy dependent [92]. 
 Since MVs can interact and be internalized within target 
cells, they may act as a widespread mechanism for horizontal 
cell-to-cell transfer of genetic information. MV-mediated 
delivery of mRNA and miRNA from donor to recipient cell 
has been shown in several laboratories [77, 95-99]. MVs can 
enter into target cells and induce specific transcription of 
delivered mRNA [97]. The patterns of secreted RNAs may 
vary in changing the conditions suggesting that secretion of 
RNAs via MVs is a regulated and adaptive process. 
 MV biological action may result from the complex of 
specific and synergic molecular combinations with a pre-
programmed composition of proteins, lipids, and nucleic 
acids [100]. In this regard, the physiological functions of 
MVs may differ from the sum of predicted effects of their 
transported molecules. In addition, the biologic effects may 
vary depending on the metabolic state of the recipient cell. 
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 Table 1 presents some molecules contained in MVs 
derived from human MSCs that may take part in tissue 
regeneration. 
PLEYOTROPIC BIOLOGICAL ACTIVITIES OF MVs 
 MVs contain a plenty of biological active molecules, 
which are not a random sample of the cytosol of the cell of 
origin. This chemical composition resulting from an energy-
depended and highly controlled process suggests that MVs 
play an important biological role (Fig. 1). The first 
hypothesis was that MVs could be a mechanism of 
molecular throw-out [101]. Exocytose-like mechanism for 
removal of superfluous or harmful molecules is well 
described. This is the case of transferrin receptors that must 
be rapidly removed from reticulocytes to allow their 
differentiation into mature red blood cells that are dismissed 
through exocytosis [26]. However, more recently, it is 
becoming clear that MVs act as an intercellular mediator of 
communication able to influence several processes such as 
migration, proliferation, differentiation, angiogenesis, 
chemotherapy resistance, immunoregulation, inflammation, 
coagulation, and cancer metastasis [22, 27, 28, 34, 63, 102, 
103] 
 A proper coordination of different tissues in the organism 
requires communication among cells. Such communication 
is guaranteed not only by membrane surface molecules (e.g., 
Notch, EGFR) and soluble secreted proteins (e.g., growth 
factors, interleukins) but also by MVs. In this context, MVs 
can deliver within a defined microenvironment as well as at 
long distances proteins and nucleic acids. MVs could be a 
unique way for the transport of soluble molecules, that have 
not an export signal peptide in their sequences (IL-1? or 
basic FGF) [36, 104] or for nucleic acids, which are very 
sensitive to nucleases present in the extracellular fluids. In 
addition, MV transport prolongs the extracellular life of 
secreted molecules (e.g., VEGF), alters their gradient (Wnt 
and MMPs) and concentrates and integrates molecular 
partners at specific sites [34, 105, 106]. All types of MVs 
carry adhesion molecules on their surface, which are 
necessary for their entry into recipient cells. Blocking 
antibodies for various integrins, adhesion molecules or 
tetraspannins significantly reduced MV capture [21, 107, 
108]. The mechanisms possibly involved in the interaction of  
 
Table 1. Molecules Involved in Tissue Regeneration which are Expressed by MSC-Derived MVs 
 
Molecule Function References 
Proteins 
Growth factors and cytokines 
(VEGF, FGF, PDGF, leptin, TNF?, TGF-?, IL-8, IL-6, 
IL-1, NGF, BDNF, NT3, NT4, GDNF) 
Activation of blood vessel and axonal growth and survival; leukocyte 
recruitment and activation 
[118-121] 
Matrix metalloproteases 
MMP9, MMP2, MT1-MMP, EMMPRIN (MMP 
activator) and TIMPs (MMP inhibitors) 
Proteolysis of extracellular matrix, cell migration [122] [123] 
Membrane proteins and receptors 
Dll4, Tspan8, Notch 
Navigation molecules for vessels and axons [113] [124, 125] 
mRNA 
IL1RN 
MT1X 
Immune regulation [21] 
CRLF1 Promote survival of neuronal cells [21] 
COL4A2, IBSP Extracellular matrix proteins [21] 
MAGED2, CEACAM5, COL4A2, SCNN1G, PKD2L2 Endothelial cell differentiation [21] 
RAX2, OR11H12, OR2M3, DDN, GRIN3A Neural cells differentiation [21] 
VEGF, HGF, IL-8 Angiogenic factors [77, 136] 
Cyclin D1, Cyclin A2, Bcl-xl, Bcl-2 Cell cycle regulation, proliferation [134] 
Oct-4, GATA-2, GATA-4, SCL, Nanog, Rex-1, HoxB4 Stem cell expansion, pluripotency [134] 
microRNA 
miR-21, miR-22 differentiation of stem cells [162-164] 
miR-21, miR-17-3p Proangiogenic action [96] 
miR-222 Antiangiogenic action [96] 
lipids 
Sphingomyelin Lipid involved in cell signaling, angiogenesis, nerve growth [165] 
Phosphatidylserine Template for other proteins such as prothrombinase complex assembly [42, 43] 
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MVs with target cells are: 1) MV membrane proteins can 
interact with receptors in a target cell and activate 
intracellular signaling (direct stimulation of target cells); 2) 
MVs can fuse with the target cell membrane and release their 
contents inside the recipient target cell. This leads to 
modification of the recipient cell membrane with the 
addition of new membrane receptors and changes of lipid 
compositions. Moreover, MV inner molecules (protein, 
mRNA and miRNA) can activate a cascade of signaling 
events in the recipient target cells. 
MVs may Act as Signaling Complexes by Direct 
Stimulation of Target Cells 
 MVs could carry several types of receptors and surface 
molecules including TF, TNF, MHC Class I/II, CCR5 
chemokine receptor [100, 109]. Through these molecules 
MVs can interact with the target cell in a juxtacrine fashion, 
thereby activating the target cell. For example, MVs carrying 
inter cellular adhesion molecule 1 (ICAM1) can be captured  
 
by lymphocyte function-associated antigen 1 (lFA1; a ligand 
for ICAM1), on the surface of CD8+ dendritic cells and 
activate T cells [110, 111]. One of the most important step in 
the development pathway which involves Notch signaling 
can be performed through MVs, because MVs express delta-
like 4 (Dll4), a transmembrane Notch ligand. Therefore, 
MVs may activate angiogenesis and axon growth by 
interacting with Notch receptors expressed by endothelial or 
nerve cells respectively [112, 113]. MV receptors can 
determine immunotolerance of cancer cells: cell death ligand 
(FasL) exposed on tumour cell-derived MVs is lethal for 
Fas-expressing lymphoid cytotoxic effector cells [114]. 
Another possible mechanism of target cell activation 
includes enzyme cleavage of MV membrane proteins and 
following action of resulting molecules as ligands for 
receptors expressed by target cells. Interestingly, some of the 
exosomal membrane proteins are not identified in the cell 
surface of the originating cell (e.g., LAMP-2) [72] 
suggesting that MVs may act as a carrier for specific proteins 
to be delivered to target cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Pleyotropic biologic effects of MVs and potential involvement in tissue repair. The physiological response to injury involves 
several overlapping phases including inflammatory response, new vessel and tissue formation and finally remodeling. Inflammation is aimed 
to remove damaged cells whereas regeneration is aimed to replace the cell loss. Finally remodeling is required for the achievement of the 
original tissue architecture. In this contest, MVs secreted by MSCs may contribute to coordinate the regenerative response as they contain 
molecules that may stimulate angiogenesis, axon growth, protect cells from apoptosis and act as immunoregulators. This cocktail may 
enhance tissue repair after injury. Some of these molecules take part in multiple processes, for example, VEGF has proangiogenic and 
neurotrophic function, Dll4 and EPHB3 regulate directional growth of vessels and axons and whereas some of the proteins induce 
proliferaion others start differentiation. ANGPT, angiopoietin; BDNF, brain derived neurotrophic factor, bFGF, basic fibroblast growth 
factor; Dll4, Delta like ligand 4; EMMPRIN, extracellular matrix metalloproteinase inducer; EPHB3, Ephrin type-B receptor 3; GDNF, glial 
cell derived neurotrophic factor; ILs, interleukins; Mif, macrophage migration inhibitory factor; MMPs, Matrix metalloproteinases; MSC, 
mesenchymal stem cell; MVs, microvesicles; NGF nerve growth factor, Notch, neurogenic locus notch homolog protein; NT3 neurotrophic 
factor 3; NT4, neurotrophic factor 4; PDGF, platelet derived growth factor; TGF-?, Transforming growth factor beta; TIMPs, tissue 
inhibitors of metalloproteinases; TNF?, tumor necrosis factor-alpha, Tspan8, tetraspanin 8; VEGF, vascular endothelial growth factor; Wnt3, 
wingless-type MMTV integration site family, member 3. 
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MVs may Act by Transferring Receptors Among Cells 
 MV fusion with the target cell leads to transfer of 
membrane proteins and lipids. For example, chemokine 
receptors, especially CCR5 or CXCR4 [115], which are 
necessary for HIV infection, are transferred via MVs to 
different types of cells and induce susceptibility to viral 
infection in these cells [109, 115-117]. MVs from tumor 
cells contain and transfer the oncogenic form of epidermal 
growth factor receptor (EGFR), which induces an 
oncotransformation of recipient cells [31]. The previously 
mentioned Notch ligand Dll4 can be transferred from MVs 
to endothelial cells and incorporated into their membrane 
resulting in inhibition of Notch signaling. Transfer of Dll4 
has been shown in vivo from tumor cells to host endothelium 
[113]. 
MVs may Deliver Proteins to the Target Cells 
 MVs carry also soluble proteins that can be transferred 
into recipient cells resulting in changes in cellular responses. 
For instance, endothelial cell-derived MVs can activate 
angiogenesis through the transfer of pro-angiogenic 
molecules such as growth factors (VEGF, bFGF, PDGF, 
leptin, FGFa, TNF?, and TGF-? and others [118-121]), 
proteases (e.g., MMP9, MMP2 and MT1-MMP) [122] and 
their activator (EMMPRIN) [123], navigation molecules 
Dll4 [113]or Tspan8 [124, 125]. Moreover, MVs also 
influence gene transcription by transferring transcription 
factors, such as peroxisome proliferator-activated receptor 
gamma (PPAR) and retinoid receptor (RXR) [126]. MVs are 
able to induce apoptosis in target cells by transferring 
caspase-1 from lipopolysaccharyde-activated monocytes 
[127, 128] or promote cell infection by transferring from 
infected cells the immunodeficiency virus or prions [85, 
129]. 
 This MV-depended transport of growth factors, their 
receptors, anti- or pro-apoptotic or toxic molecules may 
promote cooperative events and activate defined processes 
within a heterogeneous cellular population. 
MVs may Mediate a Horizontal Transfer of Genetic 
Information 
 As mentioned above, MVs may transfer among cells 
mRNA [102, 130], microRNA [77, 96, 131] and DNA [132] 
MVs are enriched of RNA molecules specific for the cell of 
origin. The fact that MVs contain specific patterns of RNA 
that may change under different conditions suggests that 
secreted RNA plays an important biological role in the 
organism. Indeed, the RNA content of MVs may vary in 
different cell culture conditions; for instance, exosomes 
released by mouse mast cells exposed to oxidative stress, can 
influence the response of other cells to the oxidative stress 
[133]. 
 The relevance of this transfer of genetic information 
among cells has been shown during differentiation [134], 
inflammation [77], regeneration [135] and cancer [136]. It 
has been shown that embryonic stem cells through MV-
secreted RNAs are able to promote clonogenicity of 
hematopoietic stem cells and induce the expression of Oct4, 
Nanog, Rex and other genes associated with stemness [134]. 
MVs released from endothelial progenitor cells activate an 
angiogenic program in quiescent endothelial cells by a 
horizontal transfer of selected patterns of pro-angiogenic 
mRNA that are translated into proteins within the recipient 
cells [102, 130]. It has been also shown that RNA shuttled 
by MVs secreted from endothelial cells promotes 
angiogenesis in tumor [136]. Tissue-specific mRNA and 
miRNA can be transferred between cells and induce tissue-
specific gene expression in other cells as recently shown by 
Aliotta and co-workers [97]. 
ROLE OF MV-MEDIATED CELL-TO-CELL 
INTERACTION IN STEM CELL BIOLOGY 
 Like other cell types also stem cells may release MVs. 
MVs derived from stem cells are able to reprogram target 
cells, for example hematopoietic progenitors [134], 
endothelial cells [130], kidney cells [137] and liver cells 
[138] suggesting that MVs are a stem cell instrument for 
tissue development regulation, regeneration, and cell 
differentiation. It is known that resident stem cells are 
present in all adult tissues [139] and that they participate in 
development and repair processes. They are situated in 
specific niches with differentiated cells. Stem cells and 
differentiated tissue cells are in strong dependence on each 
other [140, 141]. The stem/differentiated cell communication 
regulates the balance between self-renewal and 
differentiation, that helps tissue to develop, to adapt and to 
repair [140]. MVs derived from stem cells may be one of the 
crucial components supporting self-renewal and expansion 
of stem cells in the niche [102, 134]. Ratajczak et al. [134] 
showed that MVs released from embryonic stem cells are 
capable to increase pluripotency of hematopoietic 
progenitors by delivering RNA and proteins. Indeed, mRNA 
of Oct-4, Rex-1, Nanog, SCL and GATA-2 genes are highly 
enriched in MVs in respect to donor embryonic stem cells 
and MVs contain Wnt3 and Oct4 proteins. These results 
indicate that MVs are selectively enriched in mRNA during 
their formation. MVs adhere to target cells, fuse with them, 
deliver their content into the cytoplasm and the carried 
mRNAs are translated into proteins by the recipient cells 
[134]. Recently, Quesenberry and Aliotta proposed that MVs 
are an integral component of the network of environmental 
signals that allow the differentiation decision of stem cells in 
the continuum model of stem cell biology [97, 142]. 
MVs Derived from Injured Tissue may Reprogram the 
Phenotype of Bone Marrow or Resident Stem Cells 
 The participation of stem cells in the reparative processes 
of organs/tissues includes a bi-directional communication 
between stem and differentiated cells. 
 Stem cells can receive signals from injured cells able to 
induce their recruitment and differentiation. Several studies 
demonstrated that injured tissues release an increased 
number of MVs and that mRNAs specific of the damaged 
tissue are up-regulated in MVs present in blood [143-145]. 
Quesenberry and Aliotta [146] showed that injured lung cells 
are able to induce differentiation of bone marrow stem cells 
trough delivering MVs containing high levels of lung-
specific mRNAs. MVs evoke in bone marrow cells the 
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expression of lung-specific genes such as Clara cell-specific 
protein, surfactant B, and surfactant C. 
 We can hypothesize that the MVs derived from injured 
tissues may organize resident stem cells to tissue repair by a 
paracrine effect. 
MVs Derived from Stem Cells may Reprogram Cells 
Survived to Injury and Favor Tissue Regeneration 
 Stem cells stimulate tissue-specific cells to proliferate, 
protect them from apoptosis and induce progenitor cell 
differentiation. It has been shown that MSCs stimulate 
kidney [147], myocardial and vascular regeneration [17, 18, 
148, 149], reduce inflammation and promote lung repair 
[150], enhance nerve and vessels growth mostly through a 
paracrine mechanism [2, 13]. In fact, MSCs enhance resident 
cell proliferation after injury and decrease cell apoptosis, but 
do not usually incorporate into the tissues [147]. It has been 
shown that even conditioned media from MSCs stimulated 
migration and proliferation of resident cells, inhibited 
apoptosis, increased survival, and limited tissue injury [147, 
151]. These results suggest that the permanent engraftment 
of MSCs is not necessary for tissue repair and support the 
contention that they act by a paracrine/endocrine mechanism. 
 Plenty of paracrine factors have been involved in stem 
cell-dependent regeneration. They include not only soluble 
factors, but also the proteins and RNA carried by MVs 
released by these cells. Molecules delivered by MVs may 
induce differentiation of resident stem cells, viability support 
of differentiated cells survived to injury, and may activate 
tissue remodeling. It has been shown that MVs released from 
MSCs are able to enter in the epithelial cells of kidney [21] 
or hepatocytes [138], delivering their contents. This 
stimulates in vitro proliferation and apoptosis resistance of 
tissue-specific cells, and in vivo, accelerates the functional 
and morphological recovery of kidney and liver tissues [21, 
138]. RNA plays the key role in this action. Indeed, stem 
cell-derived MVs contain specific sets of RNA that can 
reprogram differentiated cells to a more pluripotent stage. 
RNA destruction in MVs significantly reduced both the in 
vitro and the in vivo effects of MVs, suggesting a mechanism 
dependent mainly on RNA delivery. 
 Based on these data, one can speculate that MVs may be 
a prospect therapeutic tool free of possible tumorigenicity or 
stem cell-elicited immune response. 
THERAPEUTIC POTENTIAL OF STEM CELL-
DERIVED MVs IN TISSUE REPAIR 
 It has been shown that MVs may regulate angiogenesis 
by promoting endothelial cell migration, proliferation, 
invasion, and tube formation [100, 121, 130, 152]. Molecular 
mechanisms include different types of biological active 
molecules carried by MVs (Fig. 1). Some of them are lipids 
such as sphingomyelin and arachidonic acid [153]. Most of 
the angiogenic stimulators are proteins such as matrix 
metalloprotease (MMP)-2 and MMP-9 [122], TF [154], 
leptin, TNF?, acidic fibroblast growth factor (FGFa), VEGF, 
and TGF-? [121]. In addition, MVs can enhance 
angiogenesis both in vitro and in vivo after transfer into 
recipient cells of pro-angiogenic RNA [130]. It has been 
shown that MVs from endothelial precursor cells contain 
mRNA associated with the PI3K/AKT and eNOS-signaling 
pathway [130] that play a critical role in angiogenesis [155]. 
Therefore, MVs may activate angiogenesis either by means 
of transfer of RNA or by delivering pro-angiogenic factors. 
 Based on the pleyotropic effects of MVs derived from 
stem cells, one may envisage that the administration of MVs 
favors tissue regeneration by inducing changes in the 
phenotype of tissue resident cells survived to injury (Fig. 2). 
Indeed, stem cell derived MVs retain several biological 
activities of the stem cells of origin that are relevant for 
tissue regeneration and repair. In particular, stem cell derived 
MVs contain transcripts involved in the control of cell 
survival, proliferation and differentiation. In vitro and in vivo 
experiments provide evidence that stem cell derived MVs 
may counteract apoptosis, inhibit inflammatory and immune 
response, and stimulate cell proliferation. 
 It has been shown that MSCs stimulate the regeneration 
of kidney tissue after acute kidney injury and help to 
improve functional recovery in chronic kidney diseases 
[156-158]. Similar studies indicate that MSC may improve 
the recovery of liver tissue after damage [8, 159]. 
 Bruno et al. [21] showed that MVs secreted by MSCs 
stimulate the kidney tissue repair in a manner comparable to 
MSCs. These MVs stimulate proliferation and protect 
tubular epithelial cells against apoptosis both in vitro and in 
vivo. Moreover, MSC-derived MVs protect kidney from the 
development of chronic damage following an acute injury 
[137]. Herrera et al. [138] showed that MVs derived from 
human liver stem cells increased in vitro proliferation and 
apoptosis resistance of human and rat hepatocytes and favor 
functional and morphological recovery after 70% 
hepatectomy. This effect was shown to be associated with 
specific translation of the MV-shuttled mRNA into the 
hepatocytes of treated rats [138]. Moreover, it was proved 
that the transferred RNA plays the main role in these actions, 
because the destruction of RNA in MVs significantly 
decreased their regenerative effect on kidney and liver. Of 
course these data do not exclude the participation of MV-
shuttled proteins in the regeneration process [21]. 
CONCLUSIONS 
 MVs released from stem cells retain several biological 
properties of the cell of origin. This can be exploited in 
regenerative medicine for designing therapeutic strategies 
that avoid the injection of stem cells. 
 The safety of adult human MSCs has been well 
documented in several clinical trials. There are no reports of 
relevant adverse effects of autologous or allogeneic MSC 
infusion in humans even in a limited number of long-term 
studies [3-6]. However, based on preclinical studies, some 
concern remains for development of organ fibrosis or 
tumorigenesis [160]. Stem cells once injected may in some 
cases undergo unwanted differentiation. In experimental 
animal models it has been shown that MSCs injected in the 
ischemic heart may in the long-term differentiate into bone 
[20] and in the kidney into adipocytes favoring development 
of a chronic renal failure [7]. After lung irradiation MSC  
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administration was shown to favor fibroblast and 
myofibroblast accumulation in focal pulmonary areas [161]. 
In addition, the intravenous administration of MSCs may 
induce formation of pulmonary emboli or infarctions. 
Moreover, one of the problems of MSC clinical application 
is the inherent heterogeneity of MSC population that may 
render difficult the evaluation of the potency of different 
MSC preparations as well as the comparison of different 
clinical trials. Estimation of the biological safety and 
potency of MVs should be easier than for cells, because they 
contain well defined patterns of molecules. In addition, 
allogeneic stem cells may elicit an immune response. MVs 
derived from adult stem cells do not express HLA class I or 
II antigens and, at least, in the experimental animals do not 
activate immunity [21]. The mechanism of action is mainly 
related to the delivery of proteins and mRNAs and miRNAs 
that limit the injury and activate regenerative programs in 
tissue resident cells suggesting that changes induced in the 
recipient cells are transient. The preliminary experiments in 
animals indicate MV long-term safety. Ongoing studies are 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Role of MVs released from stem cells in tissue regeneration. A. MVs released from MSCs or from resident stem cells may 
reprogram tissue injured cells by delivering proteins, mRNA and/or miRNA that induce cell cycle re-entry of these cells thus favoring tissue 
regeneration. B. The therapeutic use of stem cell-derived MVs would imply the in vitro expansion of relevant stem cells, the collection of 
cell-free supernatant and the concentration of MVs ether by ultracentrifugation or ultrafiltration techniques. Cultured stem cells may provide 
a continuous source for MVs. Once isolated, the molecular content of MVs can be defined by proteomic and gene array analysis to evaluate 
whether they carry the relevant molecules for the tissue regeneration before the injection in patients. 
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evaluating manufacturing techniques suitable for a large-
scale production of MVs from cultured stem cells based on 
ultrafiltration technologies. However, further experiments 
are needed to define disease specificity, bio-distribution and 
persistency of the biologic effects of MVs as well as the 
long-term safety before MVs may find clinical applications. 
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